Leerink Partnrs Brokers Reduce Earnings Estimates for WVE

Key Points

• Analysts at Leerink Partners have downgraded their Q3 2025 EPS forecast for WAVE Life Sciences to ($0.28), slightly below the previous estimate of ($0.27).
• WAVE Life Sciences recently reported Q2 earnings of ($0.31) per share, falling short of the consensus estimate of ($0.29).
• The stock is currently rated as a Moderate Buy by analysts, with an average target price of $20.36.

WAVE Life Sciences Ltd. (NASDAQ:WVE - Free Report) - Research analysts at Leerink Partnrs cut their Q3 2025 earnings estimates for shares of WAVE Life Sciences in a note issued to investors on Wednesday, July 30th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will earn ($0.28) per share for the quarter, down from their prior estimate of ($0.27). The consensus estimate for WAVE Life Sciences' current full-year earnings is ($1.14) per share. Leerink Partnrs also issued estimates for WAVE Life Sciences' Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.15) EPS, Q1 2026 earnings at ($0.37) EPS, Q2 2026 earnings at ($0.38) EPS, Q3 2026 earnings at ($0.30) EPS, Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($1.12) EPS and FY2027 earnings at ($0.33) EPS.

Other research analysts have also issued research reports about the stock. Wall Street Zen lowered shares of WAVE Life Sciences from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. Cantor Fitzgerald began coverage on shares of WAVE Life Sciences in a research report on Tuesday, April 29th. They issued an "overweight" rating and a $10.00 price objective for the company. Wells Fargo & Company lowered their price target on shares of WAVE Life Sciences from $24.00 to $21.00 and set an "overweight" rating for the company in a research report on Thursday, July 31st. Raymond James Financial initiated coverage on shares of WAVE Life Sciences in a research note on Wednesday, June 11th. They set an "outperform" rating and a $14.00 price objective on the stock. Finally, Oppenheimer initiated coverage on shares of WAVE Life Sciences in a research report on Monday, July 28th. They issued an "outperform" rating and a $24.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat.com, WAVE Life Sciences has a consensus rating of "Moderate Buy" and an average price target of $20.27.

WAVE Life Sciences Price Performance

WAVE Life Sciences stock traded down $0.36 during trading hours on Monday, hitting $8.19. The company had a trading volume of 586,139 shares, compared to its average volume of 1,302,787. The firm's fifty day moving average is $7.38 and its 200-day moving average is $8.26. WAVE Life Sciences has a fifty-two week low of $5.04 and a fifty-two week high of $16.74. The firm has a market capitalization of $1.30 billion, a P/E ratio of -9.14 and a beta of -0.95.

WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last released its earnings results on Wednesday, July 30th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.02). The company had revenue of $8.70 million for the quarter, compared to analyst estimates of $11.52 million.

Insiders Place Their Bets

In other news, Director Gregory L. Verdine sold 30,000 shares of the business's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $6.95, for a total transaction of $208,500.00. Following the completion of the sale, the director directly owned 282,517 shares of the company's stock, valued at $1,963,493.15. The trade was a 9.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 23.98% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Adage Capital Partners GP L.L.C. lifted its stake in shares of WAVE Life Sciences by 30.1% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 12,516,500 shares of the company's stock valued at $101,133,000 after buying an additional 2,894,396 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in WAVE Life Sciences by 63.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,098,866 shares of the company's stock worth $63,074,000 after acquiring an additional 1,972,262 shares during the period. Polar Capital Holdings Plc bought a new stake in WAVE Life Sciences during the 4th quarter worth approximately $12,370,000. MPM Bioimpact LLC increased its holdings in shares of WAVE Life Sciences by 138.5% in the 4th quarter. MPM Bioimpact LLC now owns 1,489,237 shares of the company's stock worth $18,422,000 after buying an additional 864,766 shares during the last quarter. Finally, Driehaus Capital Management LLC increased its holdings in shares of WAVE Life Sciences by 14.6% in the 4th quarter. Driehaus Capital Management LLC now owns 6,712,449 shares of the company's stock worth $83,033,000 after buying an additional 853,589 shares during the last quarter. 89.73% of the stock is currently owned by hedge funds and other institutional investors.

WAVE Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.